Cargando…

Teriflunomide promotes oligodendroglial differentiation and myelination

BACKGROUND: Multiple sclerosis (MS) is a neuroinflammatory autoimmune disease of the central nervous system (CNS) which in most cases initially presents with episodes of transient functional deficits (relapsing-remitting MS; RRMS) and eventually develops into a secondary progressive form (SPMS). Asi...

Descripción completa

Detalles Bibliográficos
Autores principales: Göttle, Peter, Manousi, Anastasia, Kremer, David, Reiche, Laura, Hartung, Hans-Peter, Küry, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851312/
https://www.ncbi.nlm.nih.gov/pubmed/29534752
http://dx.doi.org/10.1186/s12974-018-1110-z
_version_ 1783306370800418816
author Göttle, Peter
Manousi, Anastasia
Kremer, David
Reiche, Laura
Hartung, Hans-Peter
Küry, Patrick
author_facet Göttle, Peter
Manousi, Anastasia
Kremer, David
Reiche, Laura
Hartung, Hans-Peter
Küry, Patrick
author_sort Göttle, Peter
collection PubMed
description BACKGROUND: Multiple sclerosis (MS) is a neuroinflammatory autoimmune disease of the central nervous system (CNS) which in most cases initially presents with episodes of transient functional deficits (relapsing-remitting MS; RRMS) and eventually develops into a secondary progressive form (SPMS). Aside from neuroimmunological activities, MS is also characterized by neurodegenerative and regenerative processes. The latter involve the restoration of myelin sheaths—electrically insulating structures which are the primary targets of autoimmune attacks. Spontaneous endogenous remyelination takes place even in the adult CNS and is primarily mediated by activation, recruitment, and differentiation of resident oligodendroglial precursor cells (OPCs). However, the overall efficiency of remyelination is limited and further declines with disease duration and progression. From a therapeutic standpoint, it is therefore key to understand how oligodendroglial maturation can be modulated pharmacologically. Teriflunomide has been approved as a first-line treatment for RRMS in the USA and the European Union. As the active metabolite of leflunomide, an established disease-modifying anti-rheumatic drug, it mainly acts via an inhibition of de novo pyrimidine synthesis exerting a cytostatic effect on proliferating B and T cells. METHODS: We investigated teriflunomide-dependent effects on primary rat oligodendroglial homeostasis, proliferation, and differentiation related to cellular processes important for myelin repair hence CNS regeneration in vitro. To this end, several cellular parameters, including specific oligodendroglial maturation markers, in vitro myelination, and p53 family member signaling, were examined by means of gene/protein expression analyses. The rate of myelination was determined using neuron-oligodendrocyte co-cultures. RESULTS: Low teriflunomide concentrations resulted in cell cycle exit while higher doses led to decreased cell survival. Short-term teriflunomide pulses can efficiently promote oligodendroglial cell differentiation suggesting that young, immature cells could benefit from such stimulation. In vitro myelination can be boosted by means of an early stimulation window with teriflunomide. p73 signaling is functionally involved in promoting OPC differentiation and myelination. CONCLUSION: Our findings indicate a critical window of opportunity during which regenerative oligodendroglial activities including myelination of CNS axons can be stimulated by teriflunomide.
format Online
Article
Text
id pubmed-5851312
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58513122018-03-21 Teriflunomide promotes oligodendroglial differentiation and myelination Göttle, Peter Manousi, Anastasia Kremer, David Reiche, Laura Hartung, Hans-Peter Küry, Patrick J Neuroinflammation Research BACKGROUND: Multiple sclerosis (MS) is a neuroinflammatory autoimmune disease of the central nervous system (CNS) which in most cases initially presents with episodes of transient functional deficits (relapsing-remitting MS; RRMS) and eventually develops into a secondary progressive form (SPMS). Aside from neuroimmunological activities, MS is also characterized by neurodegenerative and regenerative processes. The latter involve the restoration of myelin sheaths—electrically insulating structures which are the primary targets of autoimmune attacks. Spontaneous endogenous remyelination takes place even in the adult CNS and is primarily mediated by activation, recruitment, and differentiation of resident oligodendroglial precursor cells (OPCs). However, the overall efficiency of remyelination is limited and further declines with disease duration and progression. From a therapeutic standpoint, it is therefore key to understand how oligodendroglial maturation can be modulated pharmacologically. Teriflunomide has been approved as a first-line treatment for RRMS in the USA and the European Union. As the active metabolite of leflunomide, an established disease-modifying anti-rheumatic drug, it mainly acts via an inhibition of de novo pyrimidine synthesis exerting a cytostatic effect on proliferating B and T cells. METHODS: We investigated teriflunomide-dependent effects on primary rat oligodendroglial homeostasis, proliferation, and differentiation related to cellular processes important for myelin repair hence CNS regeneration in vitro. To this end, several cellular parameters, including specific oligodendroglial maturation markers, in vitro myelination, and p53 family member signaling, were examined by means of gene/protein expression analyses. The rate of myelination was determined using neuron-oligodendrocyte co-cultures. RESULTS: Low teriflunomide concentrations resulted in cell cycle exit while higher doses led to decreased cell survival. Short-term teriflunomide pulses can efficiently promote oligodendroglial cell differentiation suggesting that young, immature cells could benefit from such stimulation. In vitro myelination can be boosted by means of an early stimulation window with teriflunomide. p73 signaling is functionally involved in promoting OPC differentiation and myelination. CONCLUSION: Our findings indicate a critical window of opportunity during which regenerative oligodendroglial activities including myelination of CNS axons can be stimulated by teriflunomide. BioMed Central 2018-03-13 /pmc/articles/PMC5851312/ /pubmed/29534752 http://dx.doi.org/10.1186/s12974-018-1110-z Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Göttle, Peter
Manousi, Anastasia
Kremer, David
Reiche, Laura
Hartung, Hans-Peter
Küry, Patrick
Teriflunomide promotes oligodendroglial differentiation and myelination
title Teriflunomide promotes oligodendroglial differentiation and myelination
title_full Teriflunomide promotes oligodendroglial differentiation and myelination
title_fullStr Teriflunomide promotes oligodendroglial differentiation and myelination
title_full_unstemmed Teriflunomide promotes oligodendroglial differentiation and myelination
title_short Teriflunomide promotes oligodendroglial differentiation and myelination
title_sort teriflunomide promotes oligodendroglial differentiation and myelination
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851312/
https://www.ncbi.nlm.nih.gov/pubmed/29534752
http://dx.doi.org/10.1186/s12974-018-1110-z
work_keys_str_mv AT gottlepeter teriflunomidepromotesoligodendroglialdifferentiationandmyelination
AT manousianastasia teriflunomidepromotesoligodendroglialdifferentiationandmyelination
AT kremerdavid teriflunomidepromotesoligodendroglialdifferentiationandmyelination
AT reichelaura teriflunomidepromotesoligodendroglialdifferentiationandmyelination
AT hartunghanspeter teriflunomidepromotesoligodendroglialdifferentiationandmyelination
AT kurypatrick teriflunomidepromotesoligodendroglialdifferentiationandmyelination